|Day Low/High||3.61 / 3.79|
|52 Wk Low/High||3.19 / 7.24|
Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million
New Human Clinical Studies Will Investigate the Role of NIAGEN® Nicotinamide Riboside in Mitochondrial Biogenesis and Systolic Heart Failure
Fourth Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million
Results of the Collaborative Study Provide Strong Preclinical Support for Nicotinamide Riboside Research in Alzheimer's Patients
ChromaDex's patent portfolio covering its key ingredient in TRU NIAGEN® remains strong
After launching in Hong Kong in September, Watsons expands TRU NIAGEN™ retail distribution to Singapore
New Research Suggests the Protective Benefits of NR May Lead to a New Therapeutic Option in Human Heart Failure
Private Placement Led By High Profile Venture Capitalists and Strategic Investors
-Company Will Host Investor Conference Call on Thursday, November 9, 2017-
Hong Kong will be the Initial Market Launch, Soon to be Followed by Additional Asian Locations
Company Appoints Tony Lau and Wendy Yu to Board of Directors
Company Will Host Investor Conference Call on Thursday, August 10, 2017
Findings from the University of Colorado Boulder Nicotinamide Riboside Human Clinical Trial, to be Presented to the Scientific Community
The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 541,781 share increase in total short interest for ChromaDex Corp , to 3,305,741, an increase of 19.60% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.